Current Clinical Trials

  • ARISE (PSP) Study – Phase II study to assess whether ABBV-8E12 can slow the progression of tau pathology in the brain and thereby slow the progression of progressive supranuclear palsy [currently enrolling]
  • ARTEMIS Project – A prospective evaluation of clinical informatics in early onset dementia including Alzheimer's disease and fronto-temporal dementia [currently enrolling]
  • AWARE (AD) Study – Phase II study trialling the monoclonal antibody ABBV-8E12 to reduce tau pathology and thereby slow the progression of the Alzheimer's disease [currently enrolling]
  • CREAD Study – Phase III study trialing crenanezumab as a passive immunisation in Alzheimer's disease (exploration of new therapies, particularly immunological therapies as immunisation for Alzheimer's disease) [currently enrolling]
  • EARLY Study –  Phase 2B/3 study trialing a beta secretase inhibitor in subjects who are asymptomatic or at risk of developing Alzheimer’s disease [currently enrolling].
  • ENGAGE Study - Phase III study trialing aducanumab passive immunisation in Alzheimer's disease (exploration of new therapies, particularly immunological therapies as immunisation for Alzheimer's disease) [currently enrolling]
  • Memory dysfunction Study – Aetiology and natural history of actue amnestic states, using MRI and EEG findings [currently enrolling] 
  • MINDSET Study  – Phase III study to assess whether a 5HT6 receptor antagonist, given in addition to donepezil, can improve cognitive function in patients with Alzheimer’s disease [enrolment completed - study ongoing]
  • MISSION-AD Study –  Phase III study using a beta secretase inhibitor (E2609) to minimise cognitive and behavioral decline in early Alzheimer's disease [enrolments opening August 2017]
  • NAVIGATE Study (to commence Dec 2016) – Phase II study trialing a BACE 1 inhibitor, compared to placebo, to slow cognitive decline in Alzheimer’s disease [currently enrolling]
  • PRIDE HD Study – Phase II study to assess the safety and tolerability of pridopidine [enrolment completed - study ongoing in open label phase]
  • STEADFAST Study – Phase III study to evaluate the safety and tolerability of 5mg of Azeliragon (TPP488) compared to placebo in participants with mild Alzheimer’s disease over an 18-month treatment period [enrolment completed - study ongoing]

Completed Trials

  • CLEARLY Study – A cross-sectional, multinational, non-interventional study to evaluate the psychometric comparability of versions of the Alzheimer’s Disease Cooperative Study Preclinical Alzheimer’s Cognitive Composite (ADCS-PACC) - study will reopen in 2018
  • EXPEDITION 2 & 3 Studies – Solanezumab passive immunisation in Alzheimer's disease (exploration of new therapies, particularly immunological therapies and immunisation for Alzheimer's disease)
  • MAYFLOWER ROAD Study – Phase II study to explore therapeutic benefit MAO-B inhibitor in moderate Alzheimer's Disease 
  • STARBRIGHT Study – Phase III study to assess whether Lu AE58054, given in addition to current medication can improve cognitive function in patients with Alzheimer’s disease
  • TRx FTD Study - Phase III study trialling LMTM in subjects with Behavioral Variant Frontotemporal 
  • TRx Alzheimer's Study - Phase III study trialling LMTM in subjects with mild to moderate Alzheimer's disease
  • TRx OLEX Study – Phase III open label study trialling LMTM in subjects with Behavioral Variant Frontotemporal Dementia and mild to moderate Alzheimer's disease